Uno studio per valutare l'efficacia, la sicurezza e la farmacocinetica di EYU688 in pazienti con febbre dengue
Uno studio randomizzato, in cieco per i partecipanti e per i ricercatori, controllato con placebo, a gruppi paralleli per valutare l'efficacia, la sicurezza e la farmacocinetica di EYU688 in pazienti con febbre dengue
The purpose of this study is to characterize the effect on dengue viral load, fever clearance time as well as on clinical signs and symptoms with the treatment of EYU688 compared with placebo in patients with dengue fever.
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Descrizione dettagliata
This is a randomized, participant- and investigator- blinded, placebo-controlled study to investigate the efficacy and safety of EYU688 administered orally in patients with dengue fever.
Due to the different PK sampling schedules applied, the study consists of two cohorts run in parallel (intensive PK [cohort 1] and sparse PK sampling [cohort 2]).
Tipo di studio
Tipo di studio
Iscrizione (Stimato)
Iscrizione
Fase
Fase
- Fase 2
Contatti e Sedi
Contatto studio
Contatto studio
- Nome: Novartis Pharmaceuticals
- Numero di telefono: +41613241111
- Email: novartis.email@novartis.com
Backup dei contatti dello studio
- Nome: Novartis Pharmaceuticals
Luoghi di studio
-
-
Amazonas
-
Manaus, Amazonas, Brasile, 69040-000
- Reclutamento
- Novartis Investigative Site
-
-
Federal District
-
Brasília, Federal District, Brasile, 71635-580
- Reclutamento
- Novartis Investigative Site
-
-
Rio Grande do Sul
-
Porto Alegre, Rio Grande do Sul, Brasile, 90560-032
- Reclutamento
- Novartis Investigative Site
-
-
Rio de Janeiro
-
Rio de Janeiro, Rio de Janeiro, Brasile, 21040-360
- Reclutamento
- Novartis Investigative Site
-
-
São Paulo
-
Sorocaba, São Paulo, Brasile, 18040-425
- Reclutamento
- Novartis Investigative Site
-
São Caetano do Sul, São Paulo, Brasile, 09521-160
- Reclutamento
- Novartis Investigative Site
-
São José do Rio Preto, São Paulo, Brasile, 15090 000
- Reclutamento
- Novartis Investigative Site
-
-
-
-
Atlántico
-
Barranquilla, Atlántico, Colombia, 080012
- Reclutamento
- Novartis Investigative Site
-
-
Santander Department
-
Bucaramanga, Santander Department, Colombia, 681017
- Reclutamento
- Novartis Investigative Site
-
-
Valle del Cauca Department
-
Cali, Valle del Cauca Department, Colombia, 760032
- Reclutamento
- Novartis Investigative Site
-
-
-
-
Karnataka
-
Belagavi, Karnataka, India, 590010
- Reclutamento
- Novartis Investigative Site
-
-
Maharashtra
-
Mumbai, Maharashtra, India, 400008
- Ritirato
- Novartis Investigative Site
-
Pune, Maharashtra, India, 411013
- Reclutamento
- Novartis Investigative Site
-
-
Rajasthan
-
Jaipur, Rajasthan, India, 302017
- Reclutamento
- Novartis Investigative Site
-
-
Tamil Nadu
-
Chennai, Tamil Nadu, India, 600113
- Reclutamento
- Novartis Investigative Site
-
-
-
-
-
Kuala Selangor, Malaysia, 68000
- Reclutamento
- Novartis Investigative Site
-
-
Pahang
-
Kuantan, Pahang, Malaysia, 25200
- Reclutamento
- Novartis Investigative Site
-
-
Perak
-
Ipoh, Perak, Malaysia, 30450
- Reclutamento
- Novartis Investigative Site
-
-
Pulau Pinang
-
Seberang Jaya, Pulau Pinang, Malaysia, 13700
- Reclutamento
- Novartis Investigative Site
-
-
Sarawak
-
Miri, Sarawak, Malaysia, 98000
- Reclutamento
- Novartis Investigative Site
-
-
-
-
-
Oaxaca City, Messico, 68020
- Reclutamento
- Novartis Investigative Site
-
Veracruz, Messico, 91855
- Reclutamento
- Novartis Investigative Site
-
-
-
-
-
Singapore, Singapore, 169608
- Reclutamento
- Novartis Investigative Site
-
-
Singapore
-
Singapore, Singapore, Singapore, 308433
- Reclutamento
- Novartis Investigative Site
-
-
-
-
-
Haiphong, Vietnam, 180000
- Reclutamento
- Novartis Investigative Site
-
Hanoi, Vietnam, 100000
- Reclutamento
- Novartis Investigative Site
-
Ho Chi Minh City, Vietnam, 700000
- Reclutamento
- Novartis Investigative Site
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Male or female, 18 - 60 years old (inclusive).
- History or presence of fever (≥ 38°C). At least one of the following criteria indicating dengue infection:
- Nausea or vomiting.
- Presence of rash, aches or pains including headache, muscle or joint pain.
- Onset of fever ≤ 48 hours prior to treatment start.
- Positive test on dengue fever.
Exclusion Criteria:
-
Participants with any of abnormalities of clinical laboratory parameters.
-
Usage of any anticoagulant drugs.
-
Current significant medical conditions or illness that the investigator considers should exclude the participants, especially those that require continuation of other medications likely to have an interaction with the study drug.
-
Pregnant or nursing (lactating) women.
-
Clinical signs and symptoms for severe dengue according to Dengue Guideline (WHO 2009) at screening.
-
Participants with any of the following abnormalities of clinical laboratory parameters at screening:
- Hemoglobin <12.0 g/dL in males; <11.0 g/dL in females
- Hematocrit >52 % in males; >46 % in females
- Absolute neutrophil count <1500/μL
- Platelet count <80,000/mm3
- Creatinine >165 μmol/L in males; >130 μmol/L in females
- Serum creatine kinase > 600 U/L
- ALT, AST levels more than 3 X upper limit of normal (ULN)
- Total bilirubin >24 μmol/L
-
Usage of PPIs (proton pump inhibitor) which could affect absorption of EYU688 due to stomach pH value increase up to 48 hours prior to screening.
-
Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception during dosing and for 4 days after stopping of investigational drug.
-
History or long-QT syndrome, or clinically significant ECG abnormalities, or any of the following ECG abnormalities at screening:
- QTcF > 450 msec (males)
- QTcF > 460 msec (females)
Other protocol-defined inclusion/exclusion criteria may apply.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Quadruplicare
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Comparatore placebo: Placebo
Matching placebo |
Matching placebo administered orally as capsules |
|
Sperimentale: EYU688
EYU688 administered by oral route |
EYU688 administered by oral route |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Viremia reduction (viral load reduction (VLR) on log scale) at 48 hours post treatment start
Lasso di tempo: From predose to 48 hours post treatment start
|
Efficacy assessment of EYU688. It will allow to quantify the viremia reduction at 48 hours post treatment start from baseline. |
From predose to 48 hours post treatment start
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Time from fever onset to start of the first 48 hours period during which the oral temperature remained below 37.5℃
Lasso di tempo: From fever onset to Day 15
|
Efficacy assessment of EYU688. It will allow to assess the time needed between fever onset and defervescence. |
From fever onset to Day 15
|
|
Time from fever onset to the first of two consecutive negative viremia by PCR
Lasso di tempo: From fever onset to Day 15
|
Efficacy assessment will allow to assess the viremia kinetic from treatment start to Day15 |
From fever onset to Day 15
|
|
Area under the log-transformed viremia curve (AUC) from the first dose to Day 15
Lasso di tempo: From fever onset to Day 15
|
Efficacy assessment will allow to assess the viremia kinetic from treatment start to Day 15 |
From fever onset to Day 15
|
|
Changes of viral load over time
Lasso di tempo: From baseline to Day 15
|
Efficacy assessment will allow to assess the viremia kinetic from treatment start to Day15 |
From baseline to Day 15
|
|
Incidence and severity of Adverse Events (AEs)
Lasso di tempo: From inclusion to Day 15
|
Incidence and severity of AEs by treatment group, including changes in vital signs, electrocardiograms (ECGs) and laboratory results qualifying and reported as AEs. |
From inclusion to Day 15
|
|
Incidence and severity of Serious Adverse Events (SAEs)
Lasso di tempo: From inclusion to Day 35
|
Incidence and severity of SAEs by treatment group |
From inclusion to Day 35
|
|
Change of white blood cell count over time from baseline
Lasso di tempo: From baseline to Day 15
|
Assessment of safety and tolerability of EYU688 |
From baseline to Day 15
|
|
Change of platelet count over time
Lasso di tempo: From baseline to Day 15
|
Assessment of safety and tolerability of EYU688 |
From baseline to Day 15
|
|
Change of hematocrit level and percentage increase from baseline over time
Lasso di tempo: From baseline to Day 15
|
Assessment of safety and tolerability of EYU688 |
From baseline to Day 15
|
|
Change of AST, ALT levels over time
Lasso di tempo: From baseline to Day 15
|
Assessment of safety and tolerability of EYU688 |
From baseline to Day 15
|
|
No warning signs by day 7 of fever onset
Lasso di tempo: From inclusion to Day 15
|
Assessment of the dengue fever clinical evolution under EYU688 |
From inclusion to Day 15
|
|
Diagnosis of severe dengue fever
Lasso di tempo: From inclusion to Day 15
|
Assessment of the dengue fever clinical evolution under EYU688 |
From inclusion to Day 15
|
|
Diagnosis of dengue hemorrhagic fever (DHF)
Lasso di tempo: From inclusion to Day 15
|
Assessment of the dengue fever clinical evolution under EYU688 |
From inclusion to Day 15
|
|
Plasma leakage
Lasso di tempo: From inclusion to Day 15
|
Assessment of the dengue fever clinical evolution under EYU688 |
From inclusion to Day 15
|
|
Requiring fluid infusion
Lasso di tempo: From inclusion to Day 15
|
Assessment of the dengue fever clinical evolution under EYU688 |
From inclusion to Day 15
|
|
Time from fever onset to clinical recovery
Lasso di tempo: From fever onset to Day 15
|
Assessment of the dengue fever clinical evolution under EYU688 |
From fever onset to Day 15
|
|
PK parameter (Cmax)
Lasso di tempo: From Day 1 to Day 6
|
Pharmacokinetic assessment of EYU688 in dengue fever patients |
From Day 1 to Day 6
|
|
PK parameter (Tmax)
Lasso di tempo: From Day 1 to Day 6
|
Pharmacokinetic assessment of EYU688 in dengue fever patients |
From Day 1 to Day 6
|
|
PK parameter (partial AUCs)
Lasso di tempo: From Day 1 to Day 6
|
Pharmacokinetic assessment of EYU688 in dengue fever patients |
From Day 1 to Day 6
|
|
PK concentrations following multiple doses
Lasso di tempo: From Day 1 to Day 6
|
Pharmacokinetic assessment of EYU688 in dengue fever patients |
From Day 1 to Day 6
|
Collaboratori e investigatori
Sponsor
Sponsor
Pubblicazioni e link utili
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Inizio studio
Completamento primario (Stimato)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- CEYU688A12201
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com.
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .